ML234 is a dual inhibitor targeting EZH2/LSD1, with IC50 values of 0.09 and 0.12 µM, respectively. It demonstrates strong antiproliferative effects on prostate cancer cell lines LNCAP, PC3, and 22RV1. Additionally, ML234 inhibits tumor growth in a 22RV1 xenograft mouse model, showing potential as a research agent in prostate cancer therapeutics.
Target:
Histone Methyltransferase
* VAT and and shipping costs not included. Errors and price changes excepted
